← All trials
NCT03884556
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2019
- Primary completion
- Mar 31, 2020
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tizona Therapeutics, IncLead sponsor
- SCRI Development InnovationsOverall official - principal investigator
- Sylvester Comprehensive Cancer CenterOverall official - principal investigator
- NEXT OncologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.